Latest news
Life insurers are moving from pricing metabolic risk to trying to reduce it
At the 2026 LIMRA Annual Conference, insurers and health companies argued that obesity, diabetes and insulin resistance should be treated not only as underwriting risks but as modifiable drivers of mortality, disability and claims.
Duchenne’s Accelerated Approval Faces Its Test
The Screwworm Border Did Not Hold. Now Mexico and the U.S. Are Betting on Flies.
New nicotine products could become the next major cardiovascular policy failure
Childhood obesity is the next cardiometabolic crisis already unfolding
IPM Brief – Issue 8 | The Trial Is Now a Border
Europe Opens Another Lung Cancer Door to China-Origin Immunotherapy
In Australia, Cancer Medicine Delays Cost More Than Time
Neurology Is Trying to Stop Nerves Dying, Not Just Treat What Is Left
South Sudan Has a New Health Deal. Now It Needs a Delivery System.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.